These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35338549)

  • 1. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
    Ryom L; De Miguel R; Cotter AG; Podlekareva D; Beguelin C; Waalewijn H; Arribas JR; Mallon PWG; Marzolini C; Kirk O; Bamford A; Rauch A; Molina JM; Kowalska JD; Guaraldi G; Winston A; Boesecke C; Cinque P; Welch S; Collins S; Behrens GMN;
    HIV Med; 2022 Sep; 23(8):849-858. PubMed ID: 35338549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
    Ambrosioni J; Levi L; Alagaratnam J; Van Bremen K; Mastrangelo A; Waalewijn H; Molina JM; Guaraldi G; Winston A; Boesecke C; Cinque P; Bamford A; Calmy A; Marzolini C; Martínez E; Oprea C; Welch S; Koval A; Mendao L; Rockstroh JK;
    HIV Med; 2023 Nov; 24(11):1126-1136. PubMed ID: 37849432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
    Ryom L; Cotter A; De Miguel R; Béguelin C; Podlekareva D; Arribas JR; Marzolini C; Mallon P; Rauch A; Kirk O; Molina JM; Guaraldi G; Winston A; Bhagani S; Cinque P; Kowalska JD; Collins S; Battegay M;
    HIV Med; 2020 Nov; 21(10):617-624. PubMed ID: 32885559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.
    Ryom L; Boesecke C; Bracchi M; Ambrosioni J; Pozniak A; Arribas J; Behrens G; Mallon P; Puoti M; Rauch A; Miro JM; Kirk O; Marzolini C; Lundgren JD; Battegay M;
    HIV Med; 2018 May; 19(5):309-315. PubMed ID: 29493093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons.
    Ryom L; Boesecke C; Gisler V; Manzardo C; Rockstroh JK; Puoti M; Furrer H; Miro JM; Gatell JM; Pozniak A; Behrens G; Battegay M; Lundgren JD;
    HIV Med; 2016 Feb; 17(2):83-8. PubMed ID: 26548563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.
    Bamford A; Turkova A; Lyall H; Foster C; Klein N; Bastiaans D; Burger D; Bernadi S; Butler K; Chiappini E; Clayden P; Della Negra M; Giacomet V; Giaquinto C; Gibb D; Galli L; Hainaut M; Koros M; Marques L; Nastouli E; Niehues T; Noguera-Julian A; Rojo P; Rudin C; Scherpbier HJ; Tudor-Williams G; Welch SB;
    HIV Med; 2018 Jan; 19(1):e1-e42. PubMed ID: 25649230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
    Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.
    ; Welch S; Sharland M; Lyall EG; Tudor-Williams G; Niehues T; Wintergerst U; Bunupuradah T; Hainaut M; Della Negra M; Pena MJ; Amador JT; Gattinara GC; Compagnucci A; Faye A; Giaquinto C; Gibb DM; Gandhi K; Forcat S; Buckberry K; Harper L; Königs C; Patel D; Bastiaans D
    HIV Med; 2009 Nov; 10(10):591-613. PubMed ID: 19878352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
    Hammer SM; Eron JJ; Reiss P; Schooley RT; Thompson MA; Walmsley S; Cahn P; Fischl MA; Gatell JM; Hirsch MS; Jacobsen DM; Montaner JS; Richman DD; Yeni PG; Volberding PA;
    JAMA; 2008 Aug; 300(5):555-70. PubMed ID: 18677028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)].
    ;
    Enferm Infecc Microbiol Clin; 2014; 32(7):446.e1-42. PubMed ID: 24953253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.
    Gandhi RT; Bedimo R; Hoy JF; Landovitz RJ; Smith DM; Eaton EF; Lehmann C; Springer SA; Sax PE; Thompson MA; Benson CA; Buchbinder SP; Del Rio C; Eron JJ; Günthard HF; Molina JM; Jacobsen DM; Saag MS
    JAMA; 2023 Jan; 329(1):63-84. PubMed ID: 36454551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA
    J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).
    AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan:
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Mar; 37(3):195-202. PubMed ID: 29759422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.